Lao People's Democratic Republic
Tuberculosis profile
Population  2013 6.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.6 (2–5.6) 53 (29–82)
Mortality (HIV+TB only) 0.6 (0.42–0.82) 8.9 (6.2–12)
Prevalence  (includes HIV+TB) 33 (22–47) 488 (319–693)
Incidence  (includes HIV+TB) 13 (10–18) 197 (148–259)
Incidence (HIV+TB only) 1.4 (1.1–1.9) 21 (16–28)
Case detection, all forms (%) 31 (24–41)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.7–6.4) 24 (20–27)
MDR-TB cases among notified pulmonary
TB cases
160 (96–230) 65 (56–75)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 3 004   193
Pulmonary, clinically diagnosed 541   0
Extrapulmonary 392   0
       
Total new and relapse 4 130    
Previously treated, excluding relapses 84    
Total cases notified 4 214    
Among 3 937 new cases:
72 (2%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 88 (3%) 143 (52%) 231
Laboratory-confirmed RR-/MDR-TB cases     7
Patients started on MDR-TB treatment     4
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 462 (58)
HIV-positive TB patients 267 (11)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 208 (78)
HIV-positive TB patients on antiretroviral therapy (ART) 45 (17)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 90
Previously treated cases registered in 2012 79
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 67
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 2.4
Culture (per 5 million population) 0.8
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 2.8
% Funded domestically  
% Funded internationally 100%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data